Intragraft CD45 RO gene expression is an early marker to detect small bowel allograft rejection in rats

Peng-zhi Wang,Li-wei Zhu,Tong Liu,Xijun Zhang,Y. Qiu
DOI: https://doi.org/10.1002/(SICI)1098-2752(1999)19:7<348::AID-MICR12>3.0.CO;2-D
Microsurgery
Abstract:Wistar Furth (WF) intestinal allografts were transplanted into Sprague‐Dawley (SD) rats. Recipients were randomly allocated into the following groups: (1) no treatment; (2) cyclosporine (CsA) 6 mg/kg/day, daily, subcutaneously (s.c.; full‐dose therapy); (3) CsA 3 mg/kg/day, daily, s.c. (half‐dose therapy); and (4) CsA 3 mg/kg/day, daily, s.c. + Tripterygium Wilfordii Hook. WF (TW) 3 mg/kg/day, daily, s.c. WF rats with intestinal autografts were used as controls. CD45RO intragraft expression and its index (CD45RO/CD45), measured by reverse transcription polymerase chain reaction (RT‐PCR), were significantly elevated in untreated and half‐dose CsA‐treated allografts as early as postoperative day (POD) 4, when rejection of intestinal allografts was not detected by routine pathology. Intestinal permeability measured by Tc‐DTPA radioassay was significantly elevated in untreated allografts on POD 6. Histology showed that there was severe rejection in untreated intestinal allografts and mild rejection in allografts treated with a half dose of CsA on POD 6. There was a normal CD45RO expression, permeability, and histology in intestinal allografts treated with either a full dose of CsA or a half dose of CsA + TW. These data indicate that CD45RO intragraft gene expression is an early marker to detect intestinal allograft rejection in rats. © 1999 Wiley‐Liss, Inc. MICROSURGERY 19:348–350 1999
What problem does this paper attempt to address?